Format

Send to

Choose Destination
QJM. 2018 Feb 1;111(2):103-110. doi: 10.1093/qjmed/hcx201.

Prediction of contrast induced acute kidney injury using novel biomarkers following contrast coronary angiography.

Author information

1
Cardiovascular Research Unit, Craigavon Cardiac Centre, Southern Trust BT63 5QQ, UK.
2
Randox Laboratories Ltd, Crumlin BT29 4QY, UK.
3
Department of Nephrology, Daisy Hill Hospital, Newry BT35 8DR, UK.
4
Centre for Experimental Medicine, Queens University Belfast, Belfast BT7 1NN, UK.

Abstract

Background/Introduction:

Chronic kidney disease (CKD) is a risk factor for contrast induced acute kidney injury (CI-AKI). Contrast angiography in CKD patients is a common procedure. Creatinine is a delayed marker of CI-AKI and delays diagnosis which results in significant morbidity and mortality.

Aim:

Early diagnosis of CI-AKI requires validated novel biomarkers.

Design:

A prospective observation study of 301 consecutive CKD patients undergoing coronary angiography was performed.

Methods:

Samples for plasma neutrophil gelatinase-associated lipocalin (NGAL), serum liver fatty acid-binding protein (L-FABP), serum kidney injury marker 1, serum interleukin 18 and serum creatinine were taken at 0, 1, 2, 4, 6 and 48 h post-contrast. Urinary NGAL and urinary cystatin C were collected at 0, 6 and 48 h. Incidence of major adverse clinical events (MACE) was recorded at 1 year. CI-AKI was defined as an absolute delta rise in creatinine of ≥26.5 µmol/l or a 50% relative rise from baseline at 48 h following contrast.

Results:

CI-AKI occurred in 28 (9.3%) patients. Plasma NGAL was most predictive of CI-AKI at 6 h. L-FABP performed best at 4 h. A combination of Mehran score > 10, 4 h L-FABP and 6 h NGAL improved specificity to 96.7%. MACE was statistically higher at 1 year in CI-AKI patients (25.0 vs. 6.2% in non-CI-AKI patients).

Discussion/Conclusion:

Mehran risk score, 4 h serum L-FAPB and 6 h plasma NGAL performed best at early CI-AKI prediction. CI-AKI patients were four times more likely to develop MACE and had a trebling of mortality risk at 1 year.

PMID:
29069419
DOI:
10.1093/qjmed/hcx201
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center